Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2016
Number 1 Number 2
Number 3 Number 4

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2011, No. 3

Subscribe for 2018 year

Order this issue

Order PDF of this article

Original Articles

Number 3'2011

Combined application of interferon alfa-2b, antioxidants and specific antiviral drugs protects against lethal herpes simplex virus infection

R.R. Klimova, V. V. Malinovskaya, E.N. Vyzhlova, Yu.A. Tulenev, A.A. Kushch

Herpes simplex virus (HSV) and cytomegalovirus (CMV) are widespread in human population and infect various organs and tissues. HSV- and CMV-infections are particularly dangerous for pregnant women and newborns. The major drawbacks of antiviral drugs are their high toxicity, limited bioavailability and the emergence of drug resistance with prolonged therapy. New schemes and drugs are being tested to reduce their toxicity and preserve high antiviral activity. Our objective was to evaluate the results of multimodal anti-HSV and -CMV therapy with a new drug form (NDF) of VIFERON® in combination with antiviral drugs in vitro and in a model of lethal infection in vivo. It was shown that 20,000 IU/ml NDF in a therapeutic scheme inhibits CMV-infection in vitro by 83 %. The drug enhances specific antiviral activity of chemical preparations, which allows a considerable decrease in their concentrations: 3-fold for gancyclovir and 20-fold for acyclovir (ACV). NDF produced no toxic effects in vivo. A single intraperitoneal injection of NDF 24 h after lethal infection (20 LD50) with HSV1 protected 60% mice. The combination NDF with ACV in vivo allowed 1) to decrease the dose of both agents 10-fold: 2000 IU/ml and 5 mg/kg, respectively, in comparison with individual doses, 2) to achieve therapeutic effect within 3 days, 3) to provide a 100% protection of mice infected with 20 LD50/ml HSV1. High protective effect of multimodal therapy of lethal HSV infection in vivo results from synergisticactivities of new drug form of VIFERON® and ACV. (Cytokines and Inflammation. 2011. Vol. 10. № 3. P. 113–121.)

Keywords: herpes simplex virus, human cytomegalovirus, new drug form of VIFERON.

Contents | Next article | Previous article


© 2007-2017 Cytokines and inflammation